Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis

Abstract

Get full access to this article

View all access options for this article.

References

Seo

Hong

Kim

Kwon

Bae

JH.

Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study. BMC Cardiovasc Disord. 2025;25(1):595. doi:10.1186/s12872-025-05081-0

Danan

Benichou

Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323-1330. doi:10.1016/0895-4356(93)90101-6

Zhou

Bian

, et al Hepatotoxicity associated with statins: a retrospective pharmacovigilance study based on the FAERS database. Plos One. 2025;20(7):e0327500. doi:10.1371/journal.pone.0327500

Lehtisalo

Tarkiainen

Neuvonen

, et al Ticagrelor increases exposure to the breast cancer resistance protein substrate rosuvastatin. Clin Pharmacol Ther. 2024;115(1):71-79. doi:10.1002/cpt.3067

Dermota

Jug

Trontelj

Božič Mijovski

Ticagrelor is associated with increased rosuvastatin blood concentrations in patients who have had a myocardial infarction. Clin Pharmacokinet. 2025;64(4):565-571. doi:10.1007/s40262-025-01489-1

Cooper-DeHoff

Niemi

Ramsey

, et al The clinical pharmacogenetics implementation consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557

Lee

Ryan

Birmingham

, et al Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78(4):330-341. doi:10.1016/j.clpt.2005.06.013